Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed (Nasdaq: INSM) granted inducement equity awards to 103 new employees under its 2025 Inducement Plan, intended to comply with Nasdaq Listing Rule 5635(c)(4).
On May 29, 2026, employees received 97,091 RSUs and options on 12,850 shares at an exercise price of $106.91, with four-year vesting schedules.
Insmed (Nasdaq: INSM) announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and 30-day replay will be available on Insmed's investor relations website.
Insmed (Nasdaq: INSM) reported total Q1 2026 revenues of $306.0M, led by BRINSUPRI $207.9M (44% growth vs Q4 2025) and ARIKAYCE $98.1M (6% growth vs Q1 2025). Net loss was $163.6M ($0.76/share). Cash, equivalents and marketable securities totaled ~$1.2B.
Key operational updates: UK approval for BRINSUPRI, ENCORE Phase 3b met primary and multiplicity-controlled secondary endpoints for ARIKAYCE in MAC lung disease, PALM-PAH initiated, and the company reiterated 2026 guidance: BRINSUPRI ≥ $1B and ARIKAYCE $450–$470M.
Insmed (Nasdaq: INSM) launched Suspect Bronchiectasis (Suspect BE), an educational initiative with Ty Pennington to raise awareness and improve diagnosis of bronchiectasis. The campaign encourages people with unresolved respiratory symptoms to consult a pulmonologist and consider additional testing such as a CT scan.
The program highlights symptom overlap with COPD and asthma and directs people to SuspectBE.com and social channels for resources and Ty Pennington's caregiver story.
Insmed (Nasdaq: INSM) will present six abstracts at ATS 2026 (May 17–20), including a late-breaking Phase 3b ENCORE presentation of ARIKAYCE for newly diagnosed Mycobacterium avium complex lung disease. Additional data include a post-hoc BRINSUPRI analysis, TPIP pharmacokinetics, real-world bronchiectasis burden, and PH-ILD outcomes.
Insmed also provided an independent research grant to the American Thoracic Society for a nationwide bronchiectasis diagnosis quality initiative.
Insmed (NASDAQ: INSM) announced management presentations at two investor conferences in May 2026: BofA Securities 2026 Healthcare Conference in Las Vegas on May 12, 2026 at 1:40 p.m. PT, and the 2026 RBC Capital Markets Global Healthcare Conference in New York City on May 20, 2026 at 10:30 a.m. ET. Webcasts will be available via the company's investor relations website and archived for 30 days.
Insmed (Nasdaq: INSM) will release first-quarter 2026 financial results on Thursday, May 7, 2026 and host a conference call at 8:00 a.m. ET that day. Management will discuss financial results and provide a business update.
The live call will be webcast at www.insmed.com; a replay will be available by phone through May 14, 2026 and archived on the investor site for 90 days.
Insmed (Nasdaq: INSM) reported that the Phase 2b CEDAR study of brensocatib in adult hidradenitis suppurativa (HS) did not meet primary or secondary efficacy endpoints for either 10 mg or 40 mg arms. Insmed will discontinue its HS development program.
Safety was consistent with prior studies and no new safety signals were identified, including at 40 mg. At Week 16, AN count reductions were 45.5% (10 mg), 40.3% (40 mg) and 57.1% (placebo). Reported TEAEs: Any TEAE 55.4% (10 mg), 42.9% (40 mg), 45.7% (placebo); severe TEAE 1.4% (10 mg); serious TEAE 4.1% (10 mg), 1.4% (40 mg), 1.4% (placebo).
Insmed (Nasdaq: INSM) reported positive topline results from the Phase 3b ENCORE study of ARIKAYCE in new MAC lung disease patients. The trial met the primary endpoint (Respiratory Symptom Score change: 17.77 vs 14.66, difference 3.11 points, p=0.0299) and multiplicity‑controlled culture conversion endpoints (e.g., 87.8% vs 57.0% by Month 6).
Insmed plans an sNDA filing in H2 2026 and PMDA submission in Japan to support potential label expansion; safety was consistent with known profile with higher discontinuations and bronchospasm in the ARIKAYCE arm.
Insmed (Nasdaq: INSM) granted inducement awards to 85 new employees under its 2025 Inducement Plan on Feb 27, 2026. The grants comprised 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share.
RSUs vest over four years (25% each year). Options have a 10-year term and four-year vesting: 25% at first anniversary, then 12.5% every six months thereafter, subject to continued service.